Viking Therapeutics Inc


Prices are adjusted according to historical splits.

Viking Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$694.00 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Viking Therapeutics Inc had its IPO on 2015-04-29 under the ticker symbol VKTX.

The company operates in the Healthcare sector and Biotechnology industry. Viking Therapeutics Inc has a staff strength of 21 employees.

Stock update

Shares of Viking Therapeutics Inc opened at $9.21 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $8.68 - $9.31, and closed at $8.85.

This is a -4.12% slip from the previous day's closing price.

A total volume of 2,566,251 shares were traded at the close of the day’s session.

In the last one week, shares of Viking Therapeutics Inc have slipped by -19.1%.

Viking Therapeutics Inc's Key Ratios

Viking Therapeutics Inc has a market cap of $694.00 million, indicating a price to book ratio of 1.8654 and a price to sales ratio of 0.

In the last 12-months Viking Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Viking Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Viking Therapeutics Inc’s operating margin was 0% while its return on assets stood at -23.19% with a return of equity of -39.67%.

In Q4, Viking Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Viking Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.76 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.03. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Viking Therapeutics Inc’s profitability.

Viking Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.0683. Its price to sales ratio in the trailing 12-months stood at 0.

Viking Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$168.53 million
Total Liabilities
$21.95 million
Operating Cash Flow
$7.26 million
Capital Expenditure
Dividend Payout Ratio

Viking Therapeutics Inc ended 2023 with $168.53 million in total assets and $0 in total liabilities. Its intangible assets were valued at $168.53 million while shareholder equity stood at $145.32 million.

Viking Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $21.95 million in other current liabilities, 1000.00 in common stock, $-292049000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $36.63 million and cash and short-term investments were $155.49 million. The company’s total short-term debt was $304,000 while long-term debt stood at $0.

Viking Therapeutics Inc’s total current assets stands at $167.04 million while long-term investments were $0 and short-term investments were $118.85 million. Its net receivables were $0 compared to accounts payable of $8.53 million and inventory worth $0.

In 2023, Viking Therapeutics Inc's operating cash flow was $7.26 million while its capital expenditure stood at $0.

Comparatively, Viking Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Viking Therapeutics Inc stock is currently trading at $8.85 per share. It touched a 52-week high of $11.985 and a 52-week low of $11.985. Analysts tracking the stock have a 12-month average target price of $19.22.

Its 50-day moving average was $10.13 and 200-day moving average was $5.48 The short ratio stood at 2.55 indicating a short percent outstanding of 0%.

Around 1068.4% of the company’s stock are held by insiders while 4470.5% are held by institutions.

Frequently Asked Questions About Viking Therapeutics Inc

The stock symbol (also called stock or share ticker) of Viking Therapeutics Inc is VKTX

The IPO of Viking Therapeutics Inc took place on 2015-04-29

Similar Industry Stocks (Biotechnology)

Last Price
Public Storage (PSA-PO)
Nayax Ltd (NYAX)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.


9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121